Brief: Algernon Pharmaceuticals Receives Notice Of Allowance From European Patent Office For Repirinast For Kidney Disease
08/04/2025 12:02
April 8 (Reuters) - Algernon Pharmaceuticals Inc AGN.CD: ALGERNON PHARMACEUTICALS RECEIVES NOTICE OF ALLOWANCE FROM EUROPEAN PATENT OFFICE FOR REPIRINAST FOR KIDNEY DISEASE Source text: ID:nGNX3MtBW3 Further company coverage: AGN.CD (((( Reuters.briefs@thomsonreuters.com ;));))
Recent news on Grey Matters Health
See all newsBrief: Grey Matters Announces The Closing Of Its Equity And Convertible Debenture Private Placement Totalling CAD $1.12 Million
Brief: Algernon Announces Additional Increase To Private Placement Financing
Brief: Algernon Health Announces Private Placement
Brief: Algernon Announces Closing Of The Private Placement Financing
Brief: Algernon Announces $1 Mln Private Placement